Zacks Investment Research
14 Jul 2026, 22:51 UTC · 1h ago
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
14 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Recursion Pharmaceuticals (RXRX) is forecasted to report a quarterly revenue of $11.99 million, a decrease of 37.64% from the prior-year quarter. — Significant revenue contraction typically signals weakening business fundamentals or loss of market share.
-0.40RXRX is projected to report a quarterly EPS of -$0.25, representing a 39.02% improvement over the corresponding quarter last year. — Narrowing losses indicate an improvement in cost management or operational efficiency, though the company remains unprofitable.
+0.20The Medical - Biomedical and Genetics industry ranks in the bottom 34% of all industries based on the Zacks Industry Rank. — Broad sector weakness suggests systemic headwinds for companies operating within this specific niche.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Recursion Pharmaceuticals currently holds a Zacks Rank of #3 (Hold). — A neutral rating suggests the stock is expected to perform in line with the broader market.
+0.00Which stocks this story touches
The stock outpaced the S&P 500's daily gain and shows a projected EPS improvement over the prior year, though it retains a neutral Zacks Rank #3.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
